Last Updated : April 12, 2024
Details
Generic Name:
atogepant
Project Status:
Active
Therapeutic Area:
Migraine, prevention
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Qulipta
Project Line:
Reimbursement Review
Project Number:
SR0817-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the prevention of chronic migraine in adults with 15 headache days per month (among which 8 days are considered to be migraine days) and who have previously failed, are intolerant to, or have a contraindication to at least two migraine preventive therapies.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
The prevention of migraine in adults.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | October 30, 2023 |
|---|---|
| Call for patient/clinician input closed | December 22, 2023 |
| Clarification: - Patient input submission received from the Canadian Migraine Society and Migraine Canada | |
| Submission received | December 21, 2023 |
| Submission accepted | January 12, 2024 |
| Review initiated | January 15, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | April 02, 2024 |
| Deadline for sponsors comments | April 11, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | May 09, 2024 |
| Expert committee meeting (initial) | May 22, 2024 |
| Draft recommendation issued to sponsor | June 03, 2024 To June 05, 2024 |
| Draft recommendation posted for stakeholder feedback | June 13, 2024 |
| End of feedback period | June 27, 2024 |
Last Updated : April 12, 2024